Jump to main content
Jump to site search

Issue 8, 2012
Previous Article Next Article

Aminoacyl tRNA synthetases as targets for antibiotic development

Author affiliations

Abstract

Aminoacyl tRNA synthetases represent drug targets against which numerous small molecule natural products are available for further development into useful antibiotics. An understanding of the chemical properties, characterization of mode of action, and the elucidation of biosynthetic mechanisms for these molecules is necessary for the design of derivatives with enhanced pharmacological properties. Despite the ubiquity of small molecule natural products that inhibit tRNA synthetases, only a very small number of these compounds have been approved for clinical use. Here, we focus our discussion on tRNA synthetase inhibitor molecules of three different chemical classes, namely those derived from polyketide precursors, those that occur as phosphoramidate conjugates, and promising synthetic molecules with a mode of action that is distinct from molecules of the first two classes. Also discussed are the factors that undermine the broad-based use of some of these molecules as effective antibiotics in humans and strategies that may aid in directing the development of derivatives with improved pharmacological properties.

Graphical abstract: Aminoacyl tRNA synthetases as targets for antibiotic development

Back to tab navigation
Please wait while Download options loads

Publication details

The article was received on 03 Feb 2012, accepted on 27 Feb 2012 and first published on 06 Mar 2012


Article type: Review Article
DOI: 10.1039/C2MD20032E
Citation: Med. Chem. Commun., 2012,3, 887-898
  •   Request permissions

    Aminoacyl tRNA synthetases as targets for antibiotic development

    V. Agarwal and S. K. Nair, Med. Chem. Commun., 2012, 3, 887
    DOI: 10.1039/C2MD20032E

Search articles by author